This metabolite contains a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 close to 50% from the parent drug. Plasma concentrations of the metabolite are somewhere around forty% of These viewed for sildenafil, so the metabolite accounts for around 20% of sildenafil's pharmacologic outcomes.It is impossible to find out